The purpose of he study was to evaluate the prevalence of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK), and ROS-1 fusions in the patients with metastatic nonsquamous nonsmall cell lung carcinoma (NSCLC) and their relation with different demographic and clinical variables. Methods: A cross-sectional study was carried out on 87 adult patients >18 years of age with a confirmed diagnosis of Stage IV metastatic NSCLC. All the patients were studied for EGFR mutations, ALK, and ROS-1 fusions. The outcome measures were the presence of EGFR, ALK, and ROS-1 fusions among the patients with NSCLC and the risk association with age, gender, smoking, and tumor differentiation. Results: Out of 87 patients, 26 (29.89%) patients tested positive for EGFR mutations, 4 (4.6%) for ALK, and a single case for ROS-1 fusion. The mean age of the patients who were EGFR positive was significantly younger than the mean age of those without EGFR mutation (56.77 ± 12.01 vs. 66.6..... READ ARTICLE
Journal of Radiation and Cancer Research DOI:10.4103/jrcr.jrcr_43_21
Authors: Raghav Kesri, Hari Goyal, Geetanjali Gupta, Deepak Bharti and Richu Sharma
Driver mutations are detected in 30–35% of metastatic non-small cell lung cancer (NSCLC) patients, andmutation discordance may occur between biopsies. Therefore, false negative results for a driver mutation are reportedin some patients who may need rebiopsy. We aim to determine a clinicopathological feature (especially tumor localization), other than smoking and gender, that predicts driver mutation in metastatic non-squamous NSCLC.Methods: A total of 75 patients with driver mutation reports were included in the study. The age, gender, smokingstatus, pathology, primary tumor location, and mutation of each patient were evaluated. The relationship between theclinicopathological features and driver mutations was analyzed.Results: The median age of the patients was 66 (range: 36–85); 55 (73%) of the patients were male. A driver mutationwas detected in 23 (30.7%) patients. The rates of EGFR, ALK, and ROS1 were 22.7%, 6.7%, and 1.3%, respectively. Drivermutations were more commonly found in ..... READ ARTICLE
EJMO DOI:10.14744/ejmo.2020.13543
Authors: Cengiz Karacin, Tulay Eren, Goksen Inanc Imamoglu, Sema Turker, Fevzi Coskun Sokmen, Mustafa Altinbas
Background: Programmed death ligand 1 (PD-L1) targeting immunotherapies, as pembrolizumab and nivolumab, have significantly improved outcome in patients with non-small cell lung cancer (NSCLC). Tobacco smoking is the number one risk factor for lung cancer and is linked to 80%–90% of these cancers. Smoking during cancer therapy may influence on radiotherapy and chemotherapy outcome. We aimed to review the knowledge in immunotherapy... Conclusions: Tobacco smoking patients with NSCLC generally have a higher PD-L1 tumour proportion score and experience a better ORR of immunotherapy than no smokers. There is little evidence on the effect of smoking during immunotherapy, but one study (KEYNOTE-024) may indicate survival gains of smoking cessation. READ ARTICLE
ESMO Open DOI:10.1136/esmoopen-2018-000406
Authors: Jan Norum, Carsten Nieder